

OptimiseRx Prescribers User Guide for EMIS Web

OptimiseRx

Fully integrated with the patient record to enable the delivery of prescribing best practice and to optimise cost savings.

.....



At a Glance

OptimiseRx is fully integrated into the prescribing workflow within EMIS Web. Messages are only triggered when the patient's demographic details and medication and condition history all combine to flag a message as appropriate to that specific patient at that point in time.

OptimiseRx must be activated within your practice before it is available within EMIS Web. Please see the instructions provided separately on how to achieve this.

Best Practice Messages

Messages relating to Best Practice and messages with multiple suggested alternatives are triggered at the point of entering a new medication into the prescribing window. Once a drug is selected the patient's profile is analysed and any appropriate messages are returned.

These messages provide links out to the authoritative source of the guidance or safety indicator displayed so that the prescriber has access to the original source of the guidance. The message might suggest multiple alternative medications that may be used instead of the original medication and, subject to CCG specifications, these may be filtered so that only those medications that are locally approved can be selected from this screen.

OptimiseRx messages are structured to provide:

- **Headline message** text so the key message is rapidly understood;
- **Icon** indicating whether the message is Best Practice or Cost related;
- Buttons to **Accept** or **Reject**

The screenshot shows a 'Best practice guidance' window with the following elements:

- Expand icon:** A red box labeled 'Click to expand to reveal the full message' points to a plus sign icon on the left of the first message.
- Headline message:** A red box labeled 'Headline message' points to the main text of the first message: 'Review choice of NSAID/COX-2 (cyclo-oxygenase) inhibitor; consider prescribing either ibuprofen or naproxen.'
- Suggested alternatives:** A red box labeled 'Click this box to reveal the suggested alternatives' points to a plus sign icon on the left of the second message.
- Individual message rejection:** A red box labeled 'Reject an individual message' points to the 'Reject' button (marked with a red X) for the second message.
- Best Practice or Cost related message:** A red box labeled 'Icon indicates Best Practice or Cost related message' points to a pill icon on the left of the first message.

The messages are as follows:

- Message 1: Review choice of NSAID/COX-2 (cyclo-oxygenase) inhibitor; consider prescribing either ibuprofen or naproxen. (Buttons: Accept, Reject)
- Message 2: Consider prescribing diclofenac sodium 50mg enteric coated tablets instead of diclofenac potassium 50mg tablets. (Buttons: Accept, Reject)

OptimiseRx Prescribers User Guide for EMIS Web

When you expand a message to view the full text you will also gain access to:

- **Local or national guidance** via direct hyperlinks to the authoritative source of the guidance, providing additional detail via a single click to validate the relevance to an individual patient.
- The **patient attributes** in the record which led to the message being presented, accessed via the hyperlink: 'View the triggered rule for this patient'.

Selected Drug - **Methotrexate 10mg tablets**

Monitor liver function regularly.

Source

No record of a liver function test (LFT) was found in the PMR within the last three months. Methotrexate may cause hepatotoxicity resulting in elevations of liver enzymes, acute liver atrophy, necrosis, fatty metamorphosis, periportal fibrosis or cirrhosis, usually following chronic administration. Most authorities recommend that LFTs should be monitored before starting treatment and every 1-2 weeks until therapy is stabilised. Once methotrexate therapy is established, LFTs should be performed every 2-3 months. This is a King's Fund Safety of Prescribing

[View the triggered rule for this patient](#)

Monitor haematopoietic function regularly.

Disclaimer: The OptimiseRx module is intended for the use of healthcare professionals and provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.

To ACCEPT a Best Practice Message with Alternative Suggestions

1. Click 'Accept' against the particular message you are accepting
2. The alternative drugs dialog box is then shown, as below
3. Select the alternative you wish to proceed with and click 'Proceed'

Best practice guidance

OptimiseRx

Selected Drug - **Diclofenac potassium 50mg tablets**

Review choice of NSAID/COX-2 (cyclo-oxygenase) inhibitor; consider ibuprofen or naproxen

Source

The MHRA advise that to control symptoms. Evidence with a lower cardiovascular risk. QIPP recommends that...

[View the triggered rule](#)

Consider potassium

Source

Diclofenac potassium has a rapid onset of action for analgesic relief but is no different to diclofenac sodium for its anti-inflammatory properties. If a rapid analgesic effect is not desired, significant financial saving may be made by switching to diclofenac sodium. Both diclofenac sodium and diclofenac potassium are indicated in rheumatic disease and other musculoskeletal disorders, acute gout and...

Disclaimer: The Medicines Optimisation module is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance. [View full disclaimer.](#)

Alternative drugs

- Ibuprofen 200mg tablets
- Ibuprofen 400mg tablets
- Naproxen 250mg tablets
- Naproxen 500mg tablets

Proceed Cancel

Accept Reject

View reference information

Accept Reject

View reference information

Proceed Cancel

Cost effective prescribing messages

Cost messages inform you that a single cheaper alternative is available based on the potential savings that can be made. These messages use the dose and supply quantity to calculate the savings, they will be triggered once the quantity has been entered.

Cost Swap Recommendation

Optimise Rx

A cheaper alternative drug could be used

Original Drug	Recommended Alternative
Name Beclometasone 50micrograms/dose nasal spray	Name Beconase Aqueous 50micrograms/dose nasal spray (GlaxoSmithKline UK Ltd)
Class Generic	Class Brand
Cost £2.58	Cost £2.19

Saving £0.39

Disclaimer: The Medicines Optimisation module is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance. [View full disclaimer.](#)

- To proceed with the alternative click the 'Proceed with Alternative' button, the suggested drug will replace the original drug in the prescribing screen and where an appropriate dose string match is found, the dosage will be carried forward onto the newly selected alternative product. Proceed as normal to complete the prescription.
- Selecting the 'Proceed with Original' button will ignore the message and proceed to prescribe the original drug.
- 'Do Not Proceed' will return you to the drug selection screen

To Acknowledge an Information Message

Information messages do not require you to Accept or Reject the message as the information contains no immediate action. When you are presented with an informational message use the 'OK' button to acknowledge and close the dialog box.

Best practice guidance

Optimise Rx

Selected Drug - Methotrexate 10mg tablets

- Monitor liver function regularly.**
- Monitor haematopoietic function regularly.**

Disclaimer: The Medicines Optimisation module is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance. [View full disclaimer.](#)

First Databank

About First Databank

FDB is the UK's leading provider of drug knowledge and clinical decision support. For the past 30 years we have been enabling patient safety within clinical systems and our in-depth knowledge is relied on by thousands of clinicians and dispensing pharmacists across primary, secondary and community care.

We are the only UK drug knowledge base provider to receive NICE accreditation for the quality of our database authoring and editorial policies. Our team of analysts, informaticians, clinicians and pharmacists refresh and update the medicines database regularly in line with new evidence and national guidance.

Contact Details

For further information please contact FDB on:

Tel: 01392 440100

Email: sales@fdbhealth.com

Web: www.fdbhealth.co.uk

Visit fdbhealth.co.uk

First Databank (FDB), a subsidiary of Hearst Corporation, is the UK's leading provider of drug knowledge bases and active clinical decision support.

As the company that helped to launch the medication decision support industry, we offer more than three decades of experience in helping transform drug knowledge into actionable, targeted and effective solutions geared to improving patient care, patient safety and outcomes.



OptimiseRx

Swallowtail House, Grenadier Road, Exeter Business Park, Exeter EX1 3LH
Tel +44 (0) 1392 440 100 • Fax +44 (0) 1392 440 192 • fdbhealth.co.uk
Other Locations: San Francisco, California • Indianapolis, Indiana • St. Louis, Missouri



NICE has accredited the process used by First Databank to develop content used in Multilex drug knowledge. More information on accreditation can be found at www.nice.org.uk/accreditation. Accreditation evaluates only the processes used to develop content and excludes recommendations displayed by decision support systems in specific clinical settings as these are dependent on technical algorithms which are outside of the scope of NICE accreditation. Accreditation can be used to inform compliance with ISB 0129 - Clinical Safety Risk Management System - Manufacture of Health Software and ISB 0160 - Clinical Safety Risk Management System - Deployment and Use of Health Software, but cannot be used in isolation to release any product for clinical use.